𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The tau A0 allele in Parkinson's disease

✍ Scribed by Lawrence I. Golbe; Alice M. Lazzarini; John R. Spychala; William G. Johnson; Edward S. Stenroos; Margery H. Mark; Jacob I. Sage


Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
41 KB
Volume
16
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Parkinson's disease (PD) is primarily an α‐synucle‐ inopathy, rather than a tauopathy, but there is evidence for an indirect association of tau with the pathogenetic process in PD. We therefore assessed the frequency in PD of the tau A0 allele, a dinucleotide repeat marker that has been associated with a sporadic tauopathy, progressive supranuclear palsy (PSP). We found the A0 allele to comprise 79.2% of 758 alleles from PD patients and 71.2% of 264 control alleles (P = 0.008). We also performed a meta‐analysis of three previous reports, two of which failed to produce statistically significant results. Taken together, they also support a PD/A0 allelic association, even after correction for misdiagnosis of PSP as PD (P< 0.001). The A0/A0 genotype frequency in our patients (62.3%) did not differ significantly from that in controls (53.0%, P = 0.062), but the meta‐analysis, even after correction for misdiagnosis, showed a significant result, with P = 0.002. The frequency of A0 allele and the A0/A0 genotype were compatible with Hardy‐Weinberg equilibrium. The frequency of the A0 allele and the A0/A0 genotype in our patients with familial PD was not significantly greater than in those with sporadic PD. We conclude that the tau protein may play a small role in the pathogenesis of PD and that biochemical characterization of this role may suggest opportunities for PD prophylaxis. © 2001 Movement Disorder Society.


📜 SIMILAR VOLUMES


Cerebrospinal tau, phospho-tau, and beta
✍ Yaroslau Compta; María J. Martí; Naroa Ibarretxe-Bilbao; Carme Junqué; Francesc 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB

## Abstract Alzheimer's disease (AD)‐pathology may play a role in Parkinson's disease (PD)‐related dementia (PDD). The aim of this study was to assess cerebrospinal fluid (CSF) levels of tau, phospho‐tau, and beta‐amyloid, proposed AD biomarkers, and their relationship with cognitive function in PD

Association of the Tau haplotype with Pa
✍ Liana Fidani; Kallirhoe Kalinderi; Sevasti Bostantjopoulou; Jordi Clarimon; Anto 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

## Abstract We compared the distribution of the __Tau__ H1 haplotype and related subhaplotypes in a group of clinically diagnosed Parkinson's disease patients (n = 133) and in control individuals (n = 113) from northern Greece. We were able to detect a statistically significant overrepresentation o

Association of a monoamine oxidase B all
✍ Janice H. Kurth; Dr. Matthias C. Kurth; Shirley E. Poduslo; John D. Schwankhaus 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 685 KB

Monoamine oxidase B (MAO-B) is implicated in the cause of Parkinson's disease (PD) because of its role in metabolizing the neurotoxin l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine, and forming H,02 during dopamine metabolism. Altered MAO-B activity has been observed in PD platelets. Polymerase chain

CSF Aβ42 and tau in Parkinson's disease
✍ Thomas J. Montine; Min Shi; Joseph F. Quinn; Elaine R. Peskind; Suzanne Craft; C 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 645 KB

## Abstract We tested the hypothesis that the CSF biomarker signature associated with Alzheimer's disease (AD) is present in a subset of individuals with Parkinson's disease and Dementia (PD‐D) or with PD and Cognitive Impairment, Not Dementia (PD‐CIND). We quantified CSF Aβ~42~, total tau (T‐tau),